New MGA Paper Investigates the Economic and Budgetary Effects of the BLOCKING Act This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition. The report points out that the bill would reduce the incentive for generic...
New MGA Paper Estimates Biosimilar Savings Opportunities for Large Employers This paper estimates the savings opportunity from biosimilars in the medical benefit of a large employer-sponsored health plan, using real-world claims data. This analysis illustrates the...
MGA’s Paper on State Opioid Taxes is Referenced on The WasteWatcher blog Elizabeth Wright | The WasteWatcher (blog) “Matrix Global Advisors pointed out where the focus on fighting opioids needs to be. Approximately 36 percent of people that are misusing painkillers...
Healthcare Pubs Cite MGA Analysis of Proposed Rule to Restrict Drug Rebates This week, two healthcare publications referenced MGA’s recent report concerning the HHS OIG proposed rule to restrict drug manufacturer rebates to pharmacy benefit managers (PBMs). In...
New MGA Analysis Highlights Problems with Proposal to Restrict Drug Manufacturer Rebates This MGA analysis details concerns with a proposed rule from the Health and Human Services Office of Inspector General that would restrict drug manufacturer rebates to pharmacy...
New MGA Paper Details Downsides of Prescription Opioid Tax In a new paper sponsored by Women In Government, MGA examines why a proposed tax on prescription opioids would be ineffective and details the unintended consequences of this policy. The paper explains how,...
